New stroke drug HRS-7450 enters Mid-Stage trial

NCT ID NCT07233070

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This study tests an investigational drug called HRS-7450 in 208 people who have had an acute ischemic stroke within the past 4.5 to 24 hours. Participants receive either a low, intermediate, or high dose of the drug or a placebo. The goal is to see if the drug helps improve recovery, measured by disability scores at 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HRS-7450 injection

What this could lead to

If successful, this could point toward a new treatment to improve recovery after a stroke by reducing brain damage.

What could go wrong

This is an early Phase 2 trial with only 208 participants, so results may not confirm benefit. The drug may not work better than placebo or could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Linyi People's Hospital

    Linyi, Shandong, 276002, China

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, 510062, China